Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women
- PMID: 27473002
- PMCID: PMC5182170
- DOI: 10.1016/j.ajog.2016.07.048
Use of antimüllerian hormone to predict the menopausal transition in HIV-infected women
Abstract
Background: HIV infection has been associated with early menopausal onset, which may have adverse long-term health consequences. Antimüllerian hormone, a biomarker of ovarian reserve and gonadal aging, is reduced in HIV-infected women.
Objective: We sought to assess the relationship of antimüllerian hormone to age of menopause onset in HIV-infected women.
Study design: We used antimüllerian hormone levels measured in plasma in 2461 HIV-infected participants from the Women's Interagency HIV Study to model the age at final menstrual period. Multivariable normal mixture models for censored data were used to identify factors associated with age at final menstrual period.
Results: Higher antimüllerian hormone at age 40 years was associated with later age at final menstrual period, even after multivariable adjustment for smoking, CD4 cell count, plasma HIV RNA, hepatitis C infection, and history of clinical AIDS. Each doubling of antimüllerian hormone was associated with a 1.5-year increase in the age at final menstrual period. Median age at final menstrual period ranged from 45 years for those in the 10th percentile of antimüllerian hormone to 52 years for those in the 90th percentile. Other factors independently associated with earlier age at final menstrual period included smoking, hepatitis C infection, higher HIV RNA levels, and history of clinical AIDS.
Conclusion: Antimüllerian hormone is highly predictive of age at final menstrual period in HIV-infected women. Measuring antimüllerian hormone in HIV-infected women may enable clinicians to predict risk of early menopause, and potentially implement individualized treatment plans to prevent menopause-related comorbidities and to aid in interpretation of symptoms.
Keywords: AIDS; HIV; antimüllerian hormone; hepatitis C virus infection; menopause; ovarian reserve; viremia.
Copyright © 2016 Elsevier Inc. All rights reserved.
Conflict of interest statement
The remaining authors report no conflict of interest.
Figures
References
-
- Calvet GA, Grinsztejn BG, Quintana Mde S, et al. Predictors of early menopause in HIV-infected women: a prospective cohort study. Am J Obstet Gynecol. 2015;212:765.e1–13. - PubMed
-
- de Pommerol M, Hessamfar M, Lawson-Ayayi S, et al. Menopause and HIV infection: age at onset and associated factors, ANRS CO3 Aquitaine cohort. Int J STD AIDS. 2011;22:67–72. - PubMed
-
- Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis. 2005;41:1517–24. - PubMed
-
- Centers for Disease Control. Diagnoses of HIV infectione–United States and dependent arease–2013. HIV surveillance report. 2014 Available at: http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed October 06, 2016.
-
- Kaiser Family Foundation. The global HIV/AIDS epidemic. 2015 Available at: http://kff.org/global-health-policy/fact-sheet/the-global-hivaids-epidemic/. Accessed November 25, 2015.
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI103397/AI/NIAID NIH HHS/United States
- U01 AI031834/AI/NIAID NIH HHS/United States
- U01 AI035004/AI/NIAID NIH HHS/United States
- U01 AI034989/AI/NIAID NIH HHS/United States
- U01 AI034994/AI/NIAID NIH HHS/United States
- UL1 TR000454/TR/NCATS NIH HHS/United States
- U01 AI103401/AI/NIAID NIH HHS/United States
- UL1 TR000004/TR/NCATS NIH HHS/United States
- U01 AI103408/AI/NIAID NIH HHS/United States
- U01 AI103390/AI/NIAID NIH HHS/United States
- U01 AI034993/AI/NIAID NIH HHS/United States
- U01 HD032632/HD/NICHD NIH HHS/United States
- U01 AI042590/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials